- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:05 | Cbus completes 'solar skin' to help power new 48-storey office tower | 87 | pv magazine | Australian property investor and developer Cbus Property and construction partner Multiplex have completed the installation of a 2,679 square metre building-integrated photovoltaic (BIPV) system that... ► Artikel lesen | |
| 27.10. | CBUS private equity head set to join Roc Partners | 1 | Private Equity Wire | ||
| 28.09. | Cibus, Inc.: Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop | 2 | GlobeNewswire (USA) | ||
| 14.08. | Cibus updates Latin America rice launch to 2028 while outlining $20M-$40M biofragrance revenue opportunity | 1 | Seeking Alpha | ||
| 13.08. | Earnings Call: Cibus verfehlt Umsatzprognose für Q2 2026 - Aktie bricht nachbörslich um 16 % ein | 1 | Investing.com Deutsch | ||
| 13.08. | Transcript: Cibus Q2 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 13.08. | Cibus GAAP EPS of -$0.29 misses by $0.10, revenue of $0.99M misses by $0.71M | 1 | Seeking Alpha | ||
| 13.08. | Cibus, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| CIBUS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Cibus, Inc.: Cibus Reports Second Quarter Financial Results and Provides Business Update | 286 | GlobeNewswire (Europe) | Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly... ► Artikel lesen | |
| 11.08. | Lendlease sells half stake in two regional shopping centres to Cbus | - | Inside Retail | ||
| 14.07. | Cibus (CBUS) Welcomes Landmark EU Crop Breeding Decision | - | Insider Monkey | ||
| 23.06. | Cibus, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.06. | Cibus, Inc.: Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus | 1 | GlobeNewswire (USA) | ||
| 09.06. | Cibus names board member Craig Wichner as new CEO | 1 | Seeking Alpha | ||
| 09.06. | Cibus appoints Craig Wichner as chief executive officer | 3 | Investing.com | ||
| 09.06. | Cibus, Inc.: Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation | 314 | GlobeNewswire (Europe) | SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company" or "Cibus"), a leading agricultural technology company that develops and licenses plant traits to seed companies... ► Artikel lesen | |
| 05.06. | Cibus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Cibus outlines runway into late Q1 2027 while shifting U.S. rice launch to 2029 | 3 | Seeking Alpha | ||
| 17.03. | Cibus, Inc.: Cibus Reports Fourth Quarter Financial Results and Provides Business Update | 994 | GlobeNewswire (Europe) | SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today... ► Artikel lesen | |
| 11.12.25 | Cibus, Inc.: Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council | 545 | GlobeNewswire (Europe) | Political agreement on New Genomic Techniques (NGTs), including gene editing, advances a science-based path for plant breeding innovation and supports Cibus' plans to bring improved traits to European... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,80 | +0,90 % | 16,6 Milliarden Euro bei BioNTech, 15 neue Therapeuten bei Emyria - woran die Psychedelika-Medizin wirklich hängt | ||
| EVOTEC | 3,118 | -0,76 % | Evotec Aktie: 95 Prozent verloren - kommt jetzt die Wende? | Um die Evotec Aktie ranken sich immer wieder Spekulationen und Hoffnungen auf eine Trendwende, im Chart ist davon bislang wenig zu sehen. Lange Zeit war die 200-Tage-Linie die Hürde, an der jede Erholung... ► Artikel lesen | |
| MODERNA | 228,25 | +1,53 % | Moderna vor den Zahlen: Revolution bei Krebsimpfstoffen - doch ist die Aktie völlig überdreht? | Moderna steht nach Einschätzung von Seeking Alpha vor einem medizinischen Durchbruch in der Onkologie, zugleich aber vor einem Bewertungsproblem an der Börse. Während die Kombination aus individualisiertem... ► Artikel lesen | |
| NOVAVAX | 9,050 | -0,88 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| ILLUMINA | 194,08 | +0,83 % | Illumina Inc. Bottom Line Rises In Q3 | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) announced a profit for its third quarter that Increases, from last yearThe company's bottom line came in at $220 million, or $1.43 per share. This... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 6,980 | +1,31 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| BRAIN BIOTECH | 2,640 | +1,93 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech und Syngenta vereinbaren strategische Kooperation für nachhaltige Landwirtschaft durch synthetische Biologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Kooperation
BRAIN Biotech und Syngenta vereinbaren strategische Kooperation für nachhaltige Landwirtschaft durch synthetische Biologie... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | +4,00 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| BIOCRYST PHARMACEUTICALS | 6,894 | +2,25 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| IBIO | 0,688 | -1,64 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update | ||
| TME PHARMA | 0,105 | 0,00 % | TME Pharma NV: TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12 | ||
| PHIO PHARMACEUTICALS | 0,830 | +1,99 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting | INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical FatigueKing of Prussia, Pennsylvania--(Newsfile Corp. - November... ► Artikel lesen | |
| CELLECTIS | 0,986 | 0,00 % | Cellectis S.A. Cellectis to Report Third Quarter Financial Results on November 12, 2026 | ||
| MACROGENICS | 2,180 | +0,93 % | MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program | ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment... ► Artikel lesen | |
| FERMENTALG | 0,401 | 0,00 % | FERMENTALG: Accelerating growth in the 3rd quarter of 2026 | Libourne, November 3, 2026 - Fermentalg, a creator of natural and sustainable Biosolutions derived from microorganisms for nutrition and health, announces an acceleration in sales in the 3rd quarter... ► Artikel lesen |
CIBUS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,145 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,10 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von +8,62 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CIBUS INC finden Sie auf Wallstreet Online.